Riduttasi

Epalrestat (ONO2235), an aldose reductase inhibitor, helps manage diabetic neuropathy symptoms and slows disease progression.

Imirestat (HOE 843) is an aldose reductase inhibitor that can be used in diabetes research.

MK 0434 is a steroid 5α-reductase inhibitor and hormone antagonist associated with a significant reduction in DHT.

Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR.

Alconil is a biochemical.

Trimethoprim (NSC-106568) inhibits dihydrofolate reductase, CYP2C8, and OCT2 - an antibacterial agent.

Potent TR inhibitor with IC50: 3.3μM, also inhibits glutathione reductase (IC50: 64.8μM) and T. brucei (EC50: 1μM).

Turosteride is a small molecule steroidal 5α-reductase (5α-reductase) inhibitor.Turosteride has antitumor activity for the treatment of oncologic diseases and

Aldose reductase-IN-1 (AT-001, Caficrestat) is a highly potent inhibitor of aldose reductase.Cost-effective and quality-assured.

Fluvastatin sodium (Fluvastatin sodium salt), a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), is a commonly used cholesterol

AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM).

Gold(III) chloride inhibits thioredoxin reductase (IC50=0.065 µM) and thyroxine 5-deiodinase (IC50=0.57 µM), with anticancer and antimicrobial activities.

Isomer-Turosteride, a novel 5α-reductase inhibitor, reduces prostate DHT and has anticancer properties without raising T levels.

AKR1Cs-IN-1 (Compound 29) is an effective and broad-spectrum inhibitor of the Aldo-Keto Reductase 1C family (AKR1C1-1C4). It achieves subtype inhibition by simultaneously binding to the SP2 and SP3 pockets, thereby blocking metabolic pathways related to drug resistance. In enzyme assays, AKR1Cs-IN-1 exhibits significant inhibitory activity with IC50 values of 0.09, 0.28, 0.05, and 0.51 µM for AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively. The compound shows excellent resensitizing effects in doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR, effectively enhancing the cytotoxicity of DOX. AKR1Cs-IN-1 holds promise for research on breast cancer resistance.

Antitumor agent-195 (compound 16c) is a dual-targeting agent that simultaneously targets STAT3 and NQO1. At a concentration of 1 μM, it significantly inhibits the phosphorylation of STAT3 at the Tyr705 site and effectively induces apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells. As a substrate of NQO1, Antitumor agent-195 markedly increases ROS production, causing severe DNA damage in a dose-dependent manner. It also demonstrates strong antitumor properties in MDA-MB-231 xenograft models.

ALR2-IN-6 (compound 9) is a potent competitive inhibitor of ALR2, with a Ki value of 0.064 μM. It is applicable in research related to neuropathy, retinopathy, and nephropathy.

xnum small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.

DDHF20 is an inhibitor of Staphylococcus aureus, specifically targeting and inhibiting its thioredoxin reductase (TrxR) by acting as a competitive inhibitor at the NADPH binding site. DDHF20 shows potential for research in combating infections related to Staphylococcus aureus.

ALR2-IN-1: potent, selective inhibitor of ALR2 (IC50=1.42 μM), antiglycemic, antioxidant; for diabetes research.

Myricetin-3-O-rutinoside is a flavonol glycoside and aldose reductase inhibitor with anti-neuroinflammatory effects.